PCV36 MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION IN HEART FAILURE PATIENTS  by Chui, MA & Murray, MD
175Abstracts
index of GWBAS in EH was lower (80.0 ± 16.9 vs. 90.3
± 15.3 points; p < 0.0001) and the total complaints index
of GSCQ was higher (29.7 ± 17.4 vs. 15.9 ± 9.7 points;
p < 0.000001) compared with the healthy control.
CONCLUSIONS: Some discrepancies were revealed in
testing results of the studied QL measures in developed
and transitional societies. GWBAS and GSCQ demon-
strate sufﬁcient internal consistency reliability, convergent
and discriminate validity, as well as sensitivity and may be
used for the QL assessment in EH living in an unstable
economy. DHP seems to be less reliable, probably due to
brevity and intersected structure of subscales, and should
be applicable mainly for fast preliminary QL screening.
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OBJECTIVE: The Joint National Committee (JNC) 
on Detection, Evaluation, and Treatment of High Blood
Pressure V (1993) and VI (1997) recommended diuretics
and beta-blockers as initial antihypertensive drugs.
However, a few studies have shown a trend of the increas-
ing use of angiotensin-converting enzyme inhibitors
(ACEIs) and calcium channel blockers (CCBs), and the
decreasing use of diuretics and beta-blockers. Hyperten-
sion is one of the most common reasons for patients to
use clinic visits. The purpose of the study was to assess
the association between the different patterns of antihy-
pertensive drug use and the number of clinic visits for
essential hypertension.
METHOD: Poisson regression model was employed to
assess the association between the different patterns of
antihypertensive drug use and the number of clinic visits
by using the Medical Expenditure Panel Survey (MEPS,
1996), after controlling for confounding variables. The
study population enrolled was estimated 10,357,769
non-institutionalized adult US patients with essential
hypertension.
RESULTS: Patients with diuretics or beta-blockers had
fewer clinic visits, compared to patients with ACEIs or
CCBs (p < 0.01). Patients in good physical health had
fewer clinic visits, compared with patients in fair or poor
physical health (p < 0.05). Other signiﬁcant explanatory
variables include census region and limitations in daily
life activities. 
CONCLUSION: Patients using ACEIs or CCBs, which
were not recommended by the current JNC guidelines had
more clinic visits. This association needs to be concerned
in the management of hypertension.
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OBJECTIVE: To estimate the UK population of people
with type 2 diabetes who would be eligible for treatment
with ramipril for secondary prevention of cardiovascular
events, as deﬁned by the inclusion criteria of the MICRO
HOPE trial, as a basis for estimating the NHS budget
impact of treatment. 
METHOD: Patients were eligible to participate in the
MICRO HOPE trial if they were over 55 years of age
with diabetes and one other risk factor for cardio-
vascular disease (total cholesterol >5.2mmol/L, HDL 
cholesterol £0.9mmol/L, hypertension, known microal-
buminuria, or current smoking). Exclusion criteria
included dipstick positive proteinuria and present usage
of ACE inhibitors. We used published national prevalence
data to identify the number of people with Type 2 dia-
betes over 55 in the UK at present. In order to estimate
the percentage of these patients who would ﬁt the
MICRO HOPE inclusion criteria, we conducted a review
of the South Teeside Diabetes Register.
RESULTS: There were 6998 people with diabetes on the
South Teeside District Diabetes Register in 2000. 4,733
were over 55 years of age, and of these patients 2,777
had available data for proteinuria: 496 (18%) patient
tested positive, 2,281 (82%) were negative. 1,010 (36%)
patients had additional risk factors as well as being 
proteinuria negative and not being treated with an ACE
inhibitor. There are 816,000 people with Type 2 diabetes
who are over 55 years of age in the UK at present. We
estimate that 294,000 of these patients are eligible for
treatment with ramipril, as prescribed in the MICRO
HOPE trial, but are not presently being treated. For an
average Primary Care Trust with a population of 100,000
people, there are likely to be 493 patients eligible for
treatment. 
CONCLUSION: This estimate gives a measure of 
potential workload for NHS primary care prescribers,
and could populate a budget impact analysis study on 
the cost of implementing the MICRO HOPE trial 
recommendations.
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OBJECTIVES: To quantify medication adherence to
diuretic medication in heart failure (HF) patients and to
evaluate the relationship between adherence and health
care utilization. 
METHODS: Prospective, convenience sample; 
Adult patients with a current medical diagnosis of HF and
an active prescription for a diuretic from Wishard 
Memorial Hospital in Indianapolis, Indiana. Patients
were given a six-month supply of their diuretic in a bottle
capped with a microelectronic device (eDEM, Aprex Cor-
poration) to assess daily adherence (percentage of pre-
scribed doses taken) and scheduled adherence (percentage
of prescribed doses taken on time). Health care utiliza-
tion data were extracted from the Regenstrief Medical
Records System, which is Wishard’s clinical electronic
data repository. Data retrieved during the six-month
study period included numbers of hospitalizations and
emergency department (ED) visits classiﬁed as all reasons,
cardiac-related reasons, and heart failure-related reasons.
RESULTS: Patients (n = 42) were mostly single, middle-
aged patients with moderately severe HF. The mean daily
adherence and scheduled adherence were reported as
71.0% and 43.7%, respectively. All study patients were
hospitalized at least once during the study period and
most patients visited the ED. No relationship was found
between daily adherence and health care utilization.
However, signiﬁcant relationships were found between
scheduled adherence and both cardiac-related hospital
admissions (p = 0.0329) and cardiac-related ED visits 
(p = 0.0269). The risk of these clinical encounters
increased as scheduled adherence declined. 
CONCLUSION: These ﬁndings suggest that patients 
who are consistent with the administration of their loop
diuretic have fewer cardiac related hospitalizations and
ED visits. This result may be due to the known erratic
pharmacokinetic disposition of furosemide, the predom-
inate diuretic being used by patients in the study. Study
patients with low utilization may be taking their diuretic
at times that maximize the concentration-response rela-
tionship. This mechanism, and not the actual dose, may
contribute more to reduced utilization.
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OBJECTIVE: As lipid-lowering therapy is likely to be
long term and as many patients with hyperlipidemia 
are asymptomatic, adherence to HMG CoA Reductase
Inhibitors (statins) may be of relevance to the cost effec-
tiveness of these expensive agents. Therefore, rates of
statin usage in the Irish community setting were estab-
lished and effects on the incremental cost effectiveness
ratios (ICERs) of individual statin drugs in both primary
and secondary prevention of coronary heart disease
(CHD) calculated. 
METHODS: Non-adherence rates were established for
4,948 patients prescribed statins over an 18-month period
(Sept. 1999 to Feb. 2001) using a prescription-claims
database. A Markov model investigating the cost effec-
tiveness of statins, using Irish costs for medications and
acute myocardial infarction (AMI) treatment, Irish mor-
tality probabilities and outcomes for AMI and death from
the 4S trial for secondary prevention and the WOSCOPs
trial for primary prevention was adapted for these 
non-adherence rates. Changes in the discounted ICERs
per quality adjusted life year (QALY) were calculated.
RESULTS: Atorvastatin was the most cost-effective agent
in both primary and secondary prevention of CHD fol-
lowed by ﬂuvatstatin, simvastatin and pravastatin. ICERs
ranged from 1,172 to 3,900 Euro/QALY in secondary
prevention, increasing to 2,388 and 7,508 Euro/QALY
when non-adherence was factored. The effect in primary
prevention was even more apparent. Discounted
ICERs/QALY ranged from 17,668 Euro for atorvastatin
to 38,459 Euro for pravastatin. Effects of non-adherence
increased primary prevention ICERs to 24,663 and
57,494 Euro/QALY respectively. 
CONCLUSION: Non-adherence is rarely considered in
pharmacoeconomic evaluation. However, this study illus-
trates that non-compliance can have a signiﬁcant impact
on the cost effectiveness of all statins in the Irish setting.
This is likely to be the case for most expensive medica-
tions indicated over the long-term in all healthcare set-
tings. Therefore, the effects of non-compliance should be
considered before results from economic evaluation are
used to inﬂuence prescription choice.
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OBJECTIVES: Nonadherence is a major reason for mor-
bidity and mortality. The purpose of this study was to
determine medication adherence of patients post myocar-
dial infarction (MI). 
METHODS: Patients admitted to the University of
Michigan Medical Center with diagnosis of MI were iden-
tiﬁed consecutively and prospectively from July 1999 to
July 2000. Clinical data were obtained retrospectively
from medical records including medications at discharge.
Patients were interviewed by telephone six months after
discharge. Follow-up data included a self-reported list of
medications and a four-item adherence questionnaire.
RESULTS: Complete information was obtained from 
216 patients. The mean age was 63.4 (+12.6) years and
